ULTRAGENYX PHARMACEUTICAL INC. (RARE) Operating margin 2016–2025
ULTRAGENYX PHARMACEUTICAL INC. (RARE) operating margin by fiscal year — reported operating income divided by reported revenue.
-79.5%FY2025 · since FY2016: -186471.4% → -79.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -79.5% | +16.2 pp |
| FY2024 | -95.7% | +35.4 pp |
| FY2023 | -131.1% | +47.5 pp |
| FY2022 | -178.6% | -70.0 pp |
| FY2021 | -108.6% | +13.2 pp |
| FY2020 | -121.8% | +287.2 pp |
| FY2019 | -409.0% | +312.2 pp |
| FY2018 | -721.2% | +11872.3 pp |
| FY2017 | -12593.5% | +173877.9 pp |
| FY2016 | -186471.4% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RARE financial trends
RARE RevenueRARE Net incomeRARE Net marginRARE Gross profitRARE Gross marginRARE Operating incomeRARE Operating cash flowRARE Free cash flowRARE Capital expendituresRARE Return on equityRARE Stock buybacksRARE Dividends paidRARE Total assetsRARE Total liabilitiesRARE Shareholders’ equityRARE overview →